Safilens acquires US patent for hyaluronic acid release in lenses

Six months after it acquired the European patent, Safilens asserts itself on the ophthalmic market thanks to another well-deserved recognition: the patent for the United States.
“To continue to be competitive on the market there are only two key words: research and innovation” stated Safilens president Fernando Garbellotto. The investments we are making have enabled us to introduce to the US market the Safe Gel line, the hydrophilic component of which is integrated by adding the hyaluronic acid-based natural biopolymer, Jaluronate-Gel, an absolute revolution in the contact lens sector”.
Wellbeing and comfort are guaranteed for all American contact lens wearers; thanks to the hyaluronic acid-based natural biopolymer JALURONATE – GEL they can maintain and restore the pseudomucin of the lacrimal film to ensure constant and unaltered tear production as well as a balanced supply of oxygen.

The Safe Gel line of Safe Gel 7 Days and Safe Gel 1 Day, in addition to the more recent Safe Gel Toric 1 day for astigmatism, will be distributed in the US by Two Tower Frames, the exclusive distributor of the Safe Gel technology in the States, Canada and Central America. “Acquiring this patent for the American market is a very important milestone”, stated Two Tower Frames president Eric Sharvelle, “which allows us to offer our customers and patients in the United States the innovative Safe-Gel technology created and developed by Safilens”.
The patent is only a first step as Safilens will be bringing other important new ideas to the US.
“Safegel lenses are awaiting approval by the US Food and Drug Administration”, Eric Sharvelle continued, “and we hope to make an official announcement soon.”